- Home
- AMAC vs STRO Comparison
AMAC vs STRO Comparison
Compare AMAC & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AMAC | STRO |
|---|---|---|
| Founded | N/A | 2003 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 355.7M | 332.8M |
| IPO Year | 2026 | 2018 |
Fundamental Metrics
Financial Performance| Metric | AMAC | STRO |
|---|---|---|
| Price | $9.80 | $16.03 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $31.33 |
| AVG Volume (30 Days) | 108.4K | ★ 296.1K |
| Earning Date | N/A | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $38,419,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.79 | $0.72 |
| 52 Week High | $9.82 | $43.85 |
Technical Indicators
Market Signals| Indicator | AMAC | STRO |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 30.44 |
| Support Level | N/A | $14.81 |
| Resistance Level | N/A | $17.33 |
| Average True Range (ATR) | 0.00 | 1.05 |
| MACD | 0.00 | 0.09 |
| Stochastic Oscillator | 0.00 | 22.32 |
Price Performance
Historical ComparisonAbout AMAC AMR Resources Acquisition Corp Class A Ordinary Shares
AMR Resources Acquisition Corp is a newly formed blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more operating businesses.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.